Label: E-SE- sodium selenite and .alpha.-tocopherol acetate, d- injection, solution

  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated November 12, 2024

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    FOR VETERINARY USE ONLY

    Approved by FDA under NADA # 030-315

    PRODUCT INFORMATION

  • SPL UNCLASSIFIED SECTION

    CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION

    DESCRIPTION E-SE Injection is an emulsion of selenium-tocopherol for the prevention and treatment of myositis (Selenium-Tocopherol Deficiency) syndrome in horses. Each mL contains: 5.48 mg sodium selenite (equivalent to 2.5 mg selenium), 50 mg (68 USP units or IU) vitamin E (as d-alpha tocopheryl acetate), 250 mg polyoxyethylated vegetable oil, 2% benzyl alcohol (preservative), water for injection q.s. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

  • CLINICAL PHARMACOLOGY

    PHARMACOLOGY It has been demonstrated that selenium and tocopherol exert physiological effects and that these effects are intertwined with sulfur metabolism. Additionally, tocopherol appears to have a significant role in the oxidation process, thus suggesting an interrelationship between selenium and tocopherol in overcoming sulfur-induced depletion and restoring normal metabolism. Although oral ingestion of adequate amounts of selenium and tocopherol would seemingly restore normal metabolism, it is apparent that the presence of sulfur and, perhaps, other factors interfere during the digestive process with proper utilization of selenium and tocopherol. When selenium and tocopherol are injected, they bypass the digestive process and exert their full metabolic effects promptly on cell metabolism. Anti-inflammatory action has been demonstrated by selenium-tocopherol in the Selye Pouch Technique and experimentally induced polyarthritis study in rats.

  • VETERINARY INDICATIONS

    INDICATIONS E-SE Injection is recommended for the control of the following clinical signs when associated with myositis (Selenium-Tocopherol Deficiency) syndrome: rapid respiration, profuse sweating, muscle spasms and stiffness, elevated SGOT.

  • SPL UNCLASSIFIED SECTION

    CAUTION Intravenous administration, if elected, should be by slow injection.

    Emulsions injected intramuscularly into the horse may produce transitory local muscle soreness and can be prevented to some degree by injecting deeply (2 to 21/2 inches), in divided doses, in two or more sites. Do not continue therapy in horses demonstrating such sensitivity.

    Selenium is toxic if administered in excess. A fixed dose schedule is therefore important (read package insert for each selenium-tocopherol product carefully before using).

  • WARNINGS

    WARNINGS Anaphylactoid reactions, some of which have been fatal, have been reported in horses administered E-SE Injection. Signs include excitement, sweating, trembling, ataxia, respiratory distress, and cardiac dysfunction. These reactions have been reported as associated both with intravenous and intramuscular injections. It is presently unknown whether the mode of application affects the frequency of such reactions. However, reactions associated with intramuscular injections have been reported to manifest more slowly and hence may give more time to institute treatment for anaphylaxis, such as epinephrine and/or corticosteroid injection.

    Medications which have been reported to cause major adverse reactions in horses should be avoided when E-SE is administered, unless the condition of the animal requires such use.

    Not to be used in horses intended for food.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION Administration: slow intravenous injection (see WARNINGS) or deep intramuscular injections, in divided doses, in two or more sites in the gluteal or cervical muscles. Dosage: 1 mL per 100 pounds of body weight. May be repeated at 5-10 day intervals.

  • PRECAUTIONS

    PRECAUTIONS Selenium-Tocopherol Deficiency (STD) syndrome produces a variety and complexity of symptoms often interfering with a proper diagnosis. Even in selenium deficient areas there are other disease conditions which produce similar clinical signs. It is imperative that all these conditions be carefully considered prior to treatment of STD syndrome. Serum selenium levels, elevated SGOT, and creatine levels may serve as aids in arriving at a diagnosis of STD, when associated with other indices.

    Important Use only the selenium-tocopherol product recommended for each species. Each formulation is designed for the species indicated to produce the maximum efficacy and safety.

  • HOW SUPPLIED

    HOW SUPPLIED 100 mL sterile, multiple-dose glass vial, NDC 0061-0709-04.

    STORAGE Store between 2 and 30 C (36 and 86 F). Protect from freezing.

  • SPL UNCLASSIFIED SECTION

    Rev. 10-2022

    Copyright © 2022 Merck & Co., Inc., Rahway,
    NJ, USA and its affiliates.
    All rights reserved.
    Made in Germany.

    MERCK
    Animal Health

    399371 R2

  • PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton

    100 mL Sterile
    Multiple Dose Vial
    2.5 mg/mL

    SELENIUM

    NDC 0061-0709-04

    E-SE®
    (SELENIUM, VITAMIN E)

    Injection
    Veterinary

    Caution: Federal law restricts
    this drug to use by or on the
    order of a licensed veterinarian.

    Approved by FDA under
    NADA # 030-315

    MERCK
    Animal Health

    PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton
  • INGREDIENTS AND APPEARANCE
    E-SE 
    sodium selenite and .alpha.-tocopherol acetate, d- injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:0061-0709
    Route of AdministrationINTRAVENOUS, INTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM SELENITE (UNII: HIW548RQ3W) (SELENITE ION - UNII:KXO0259XJ1) SELENIUM2.5 mg  in 1 mL
    .ALPHA.-TOCOPHEROL ACETATE, D- (UNII: A7E6112E4N) (.ALPHA.-TOCOPHEROL, D- - UNII:N9PR3490H9) .ALPHA.-TOCOPHEROL, D-68 [USP'U]  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0061-0709-041 in 1 CARTON
    1100 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA03031507/09/1964
    Labeler - Schering Corporation (001317601)